Invasive Candida auris infection in United States, 2026: 9,844 reported cases so far

Outbreak report · United States · published 2 October 2026

By Dr Natalya Mathur, ENCLAI (Enclai LLC), Dr Gaurav Mathur. Licence CC BY 4.0.

Cite as: Dr Natalya Mathur, ENCLAI (Enclai LLC), Dr Gaurav Mathur (2026). Invasive Candida auris infection in United States, 2026: 9,844 reported cases so far. ENCLAI. https://doi.org/10.5281/zenodo.23132079

1. The outbreak

9,844 cases of invasive Candida auris infection have been reported in United States in 2026, with counts running to 20 September 2026.

That is already more than the 9,669 reported in the whole of 2025 (1.0 times as many).

Case definition: reported cases. Figures are as reported by the originating public-health authorities and compiled by ENCLAI; they are not modelled estimates.

Reported cases of Invasive Candida auris infection in United States by year
YearReported casesCoverage
20259,669full year
20269,844year to date

2. The pathogen

The organism has emerged in Latin America, where it is associated with nosocomial outbreaks and multidrug resistance.1 Reports of the pathogen in pediatric and neonatal populations have been recorded in several countries in the region.1

Candida auris is identified as a resistant fungal pathogen that challenges the clinical use of conventional antifungal agents.2

Candida auris is identified as a resistant fungal pathogen that challenges the clinical use of conventional antifungal agents.2

The pathogen is associated with persistent nosocomial outbreaks and horizontal transmission.1 Reports of the pathogen in pediatric and neonatal populations have been recorded in several countries in the region.1

3. Pathogenesis, pathophysiology and mechanisms

Candida auris is a healthcare-associated yeast that spreads rapidly within the healthcare environment.3 The organism is known to survive on human skin and in tough environmental conditions, which facilitates rapid transmission in intensive care units.4 The ability of these yeasts to form dense biofilms on plastic surfaces reinforces the role of horizontal transmission.1 In neonatal intensive care units, risk factors for serious infection include broad-spectrum antibiotic exposure, prematurity, and congenital heart disease.3 In transplant recipients, prolonged hospitalizations, intensive immunosuppression, frequent invasive procedures, and exposure to broad-spectrum antimicrobials pose a disproportionate threat.5

In neonatal intensive care units, the clinical presentation of late-onset sepsis caused by C. auris is indistinguishable from other etiologies.3 Global reports indicate that C. auris outbreaks in neonatal intensive care units are associated with high mortality.3 Available reports suggest frequent colonization in critically ill transplant recipients and high mortality among those who develop invasive disease.5

Candida auris is a healthcare-associated yeast that spreads rapidly within the healthcare environment.3 The organism is known to survive on human skin and in tough environmental conditions, which facilitates rapid transmission in intensive care units.4 The ability of these yeasts to form dense biofilms on plastic surfaces reinforces the role of horizontal transmission.1

In neonatal intensive care units, the clinical presentation of late-onset sepsis caused by C. auris is indistinguishable from other etiologies.3 Global reports indicate that C. auris outbreaks in neonatal intensive care units are associated with high mortality.3 Available reports suggest frequent colonization in critically ill transplant recipients and high mortality among those who develop invasive disease.5

Candida auris is a multidrug-resistant yeast that poses a disproportionate threat to transplant recipients because of prolonged hospitalizations, intensive immunosuppression, frequent invasive procedures, and exposure to broad-spectrum antimicrobials.5 The species is distinguished by its multidrug resistance to various types of antifungal agents, the difficulties in its microbiological identification, and its ability to cause persistent nosocomial outbreaks.1 In neonatal intensive care units, risk factors for serious infection include broad-spectrum antibiotic exposure, prematurity, and congenital heart disease.3

The identification of environmental reservoirs, colonization of healthcare personnel, and the ability of these yeasts to form dense biofilms on plastic surfaces reinforce the critical role of horizontal transmission.1 It is known to survive on human skin and tough environmental conditions, facilitating rapid transmission in ICU.4 Despite growing recognition of its propensity for skin colonization, environmental persistence, and biofilm formation on healthcare devices, standardized screening practices for transplant donors and recipients remain poorly defined.5

Global reports indicate that C. auris outbreaks in neonatal intensive care units are associated with high mortality.3 Available reports suggest frequent colonization in critically ill transplant recipients and high mortality among those who develop invasive disease.5 Mortality remains high, influenced by diagnostic delays and species characteristics.1

Candida auris is a healthcare-associated yeast that spreads rapidly within the healthcare environment.3 The organism is known to survive on human skin and in tough environmental conditions, which facilitates rapid transmission in intensive care units.4 The ability of these yeasts to form dense biofilms on plastic surfaces reinforces the role of horizontal transmission.1

Global reports indicate that C. auris outbreaks in neonatal intensive care units are associated with high mortality.3 Available reports suggest frequent colonization in critically ill transplant recipients and high mortality among those who develop invasive disease.5

4. Clinical description and complications — why the disease matters

Candida auris is a healthcare-associated yeast that has attracted attention due to its increased antimicrobial resistance and ability to spread rapidly within the healthcare environment.3 Infants admitted to the neonatal intensive care unit have risk factors such as broad spectrum antibiotic exposure, prematurity and congenital heart disease that predispose them to serious infection with C. auris.3 The clinical presentation of late onset sepsis with C. auris is indistinguishable from other etiologies.3 In neonatal intensive care units, C. parapsilosis sensu lato is usually the predominant species, frequently associated with the use of invasive devices.1 Candidozyma auris has emerged, associated with nosocomial outbreaks and multidrug resistance.1 This species is distinguished by its multidrug resistance to various types of antifungal agents, the difficulties in its microbiological identification, and its ability to cause persistent nosocomial outbreaks.1 Its impact on NICUs has been significant, with reports in pediatric and neonatal populations in several countries in the region, underscoring the urgent need for specific surveillance, infection control, and rapid response upon detection.1 Candida auris is a multidrug-resistant yeast that poses a disproportionate threat to transplant recipients because of prolonged hospitalizations, intensive immunosuppression, frequent invasive procedures, and exposure to broad-spectrum antimicrobials.5 Available reports suggest frequent colonization in critically ill transplant recipients and high mortality among those who develop invasive disease.5

Consequently, there have been global reports of C. auris outbreaks in NICUs associated with high mortality.3 Mortality remains high, influenced by diagnostic delays and species characteristics.1 Candida auris (Candidozyma auris), a human fungal pathogen, poses a significant global health threat because it frequently resists antifungal therapy, transmits efficiently in healthcare settings, and exhibits pronounced skin tropism.6 These features have enabled outbreaks in healthcare settings worldwide and have complicated the management of life-threatening invasive infections.6 Pathogens such as Candida auris, Candida albicans, and Aspergillus fumigatus are particularly problematic, as they are known to develop multidrug resistance and cause persistent infections in critically ill patients.7 These biofilms often show a much higher tolerance to standard antifungal drugs and can escape the host body's immune defenses.7 This makes the infections they cause more persistent and very difficult to treat in clinical practice.7 Another difficult-to-treat isolate is Candida auris, an emerging drug-resistant pathogen responsible for several outbreaks in the past decade.4 It is known to survive on human skin and tough environmental conditions, facilitating rapid transmission in ICU.4

Consequently, there have been global reports of C. auris outbreaks in NICUs associated with high mortality.3 Mortality remains high, influenced by diagnostic delays and species characteristics.1 Available reports suggest frequent colonization in critically ill transplant recipients and high mortality among those who develop invasive disease.5

Pathogens such as Candida auris are known to develop multidrug resistance and cause persistent infections in critically ill patients.7 Biofilms formed by these pathogens often show a much higher tolerance to standard antifungal drugs and can escape the host body's immune defenses, making the infections they cause more persistent and very difficult to treat in clinical practice.7

In neonatal intensive care units, the clinical presentation of late onset sepsis caused by Candida auris is indistinguishable from other etiologies.3 Infants admitted to the neonatal intensive care unit have risk factors such as broad spectrum antibiotic exposure, prematurity, and congenital heart disease that predispose them to serious infection with C. auris.3

In most studies, the median age at diagnosis is between 10 and 16 days of life, consistent with the clinical pattern of late-onset sepsis associated with cumulative exposure to invasive devices and antibiotics.1 Consequently, there have been global reports of C. auris outbreaks in NICUs associated with high mortality.3

More

Invasive Candida auris infection in United States: live counts and trend · Invasive Candida auris infection: all countries · Active outbreaks · How we verify

Background sections are written by the Enclai Disease Desk from public health-authority sources; each paragraph was checked sentence by sentence against its source by two independent reviews. Outbreak figures come from ENCLAI's surveillance data (export of 2026-10-02).

References

  1. Neonatal Candidemia in Latin America: Trends, Resistance, and Prevention Strategies (2008-2025).J Fungi (Basel) 2026; PMID 41893162; PMCID PMC13027495; doi:10.3390/jof12030230 · Accessed 2026-10-02
  2. The potential of bacteriocins in invasive fungal infections: Antifungal activities and intestinal protection.Microbiol Res 2026; PMID 42541938; doi:10.1016/j.micres.2026.128654 · Accessed 2026-10-02
  3. Candida auris in the neonatal intensive care unit.Semin Perinatol 2026; PMID 42142999; doi:10.1016/j.semperi.2026.152249 · Accessed 2026-10-02
  4. Dynamics of 1,3-β-D-Glucan in Invasive Candidiasis: A Narrative Review of Microbiological Aspects and Diagnostic Implications.Antibodies (Basel) 2026; PMID 42041387; PMCID PMC13113447; doi:10.3390/antib15020028 · Accessed 2026-10-02
  5. Candida auris Screening in Organ Transplantation.Transpl Infect Dis 2026; PMID 41531162; doi:10.1111/tid.70166 · Accessed 2026-10-02
  6. Antifungal drug resistance in Candida auris: molecular mechanisms and emerging therapeutic approaches.journal 2026; PMID 42736068 · Accessed 2026-10-02
  7. Antifungal peptides for biofilm disruption: Mechanisms, design strategies, and translational outlook.Microb Pathog 2026; PMID 42229743; doi:10.1016/j.micpath.2026.108601 · Accessed 2026-10-02